These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35081277)

  • 1. Krebs von den Lungen-6 levels in untreated idiopathic pulmonary fibrosis.
    Jiang D; Xiao H; Dong R; Geng J; Xie B; Ren Y; Dai H
    Clin Respir J; 2022 Mar; 16(3):234-243. PubMed ID: 35081277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Research on Prognostic Evaluation of Subjects With IPF by Peripheral Blood Biomarkers, Quantitative Imaging Characteristics and Pulmonary Function Parameters.
    Guo L; Yang Y; Liu F; Jiang C; Yang Y; Pu H; Li W; Zhong Z
    Arch Bronconeumol (Engl Ed); 2020 Jun; 56(6):365-372. PubMed ID: 31740085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
    [No Abstract]   [Full Text] [Related]  

  • 6. Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis.
    Chung C; Kim J; Cho HS; Kim HC
    Sci Rep; 2022 May; 12(1):8564. PubMed ID: 35595812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
    d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E
    Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.
    Ko UW; Cho EJ; Oh HB; Koo HJ; Do KH; Song JW
    PLoS One; 2020; 15(12):e0244114. PubMed ID: 33332430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
    Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
    Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive biomarker analysis of patients with idiopathic pulmonary fibrosis and interstitial lung disease with healthy individuals.
    Balci A; Düz ME; Vurmaz A; Çilekar Ş; Kaya F
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5468-5479. PubMed ID: 37401283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality.
    Rai M; Parthasarathi A; Beeraka NM; Kaleem Ullah M; Malamardi S; Padukudru S; Siddaiah JB; Uthaiah CA; Vishwanath P; Chaya SK; Ramaswamy S; Upadhyay S; Ganguly K; Mahesh PA
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
    Millan-Billi P; Castellví I; Martinez-Martinez L; Mariscal A; Barril S; D'Alessandro M; Franquet T; Castillo D
    Arch Bronconeumol; 2024 Jun; 60(6):350-355. PubMed ID: 38644152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy.
    d'Alessandro M; Bergantini L; Cameli P; Pieroni M; Refini RM; Sestini P; Bargagli E
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis.
    Aoshima Y; Enomoto Y; Muto S; Meguro S; Kawasaki H; Kosugi I; Fujisawa T; Enomoto N; Inui N; Nakamura Y; Suda T; Iwashita T
    Lung; 2021 Jun; 199(3):289-298. PubMed ID: 33770226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome.
    Remuzgo-Martínez S; Atienza-Mateo B; Ocejo-Vinyals JG; Genre F; Pulito-Cueto V; Mora-Cuesta VM; Iturbe-Fernández D; Lera-Gómez L; Pérez-Fernández R; Prieto-Peña D; Irure J; Romero-Bueno F; Sanchez-Pernaute O; Alonso-Moralejo R; Nuño L; Bonilla G; Vicente-Rabaneda EF; Grafia I; Prieto-González S; Narvaez J; Trallero-Araguas E; Selva-O'Callaghan A; ; ; Gualillo O; Cavagna L; Cifrián JM; Renzoni EA; Castañeda S; López-Mejías R; González-Gay MA
    Sci Rep; 2021 Nov; 11(1):22574. PubMed ID: 34799647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease.
    d'Alessandro M; Conticini E; Bergantini L; Mazzei MA; Bellisai F; Selvi E; Cameli P; Frediani B; Bargagli E
    Tissue Cell; 2024 Oct; 90():102516. PubMed ID: 39137538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum human epididymis protein 4 is associated with disease severity and worse survival in idiopathic pulmonary fibrosis: a cohort study.
    Tian M; Meng K; Gao Y; Zhang J; Xie M; Tian Y; Liu X; Ma M; Cai Y; Wu H; Ding J; Chen J; Cai H
    Ann Transl Med; 2022 Sep; 10(18):992. PubMed ID: 36267722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
    Ma H; Lu J; Song Y; Wang H; Yin S
    BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis.
    Choi MG; Choi SM; Lee JH; Kim JY; Song JW
    Respir Res; 2022 Dec; 23(1):334. PubMed ID: 36494685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.